ELF5 and breast carcinoma: This provides evidence that the effects of elevated ELF5 in MCF-7 cells also occur in three breast cancer metastases that have become resistant to endocrine therapy, consistent with elevation of ELF5 providing an additional mechanism driving acquired endocrine resistance.